IGF1 and breast carcinoma: After multivariable adjustment for baseline demographic and clinical characteristics, patients with high IGF1 had a significantly lower risk of all-cause mortality (HR, 0.53; 95% CI, 0.29–0.96) and a borderline lower risk of breast cancer-specific mortality (HR, 0.53; 95% CI, 0.27–1.02) compared with patients with low IGF1 (Table 2).